Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Finished Goods (2019 - 2025)

Aytu Biopharma (AYTU) has disclosed Finished Goods for 7 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Finished Goods fell 24.81% to $5.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.6 million, a 24.81% decrease, with the full-year FY2025 number at $8.9 million, up 45.33% from a year prior.
  • Finished Goods was $5.6 million for Q4 2025 at Aytu Biopharma, down from $7.9 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $12.0 million in Q4 2021 to a low of $5.6 million in Q4 2025.
  • A 5-year average of $8.3 million and a median of $8.4 million in 2022 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: skyrocketed 99.93% in 2021, then crashed 32.89% in 2022.
  • Aytu Biopharma's Finished Goods stood at $12.0 million in 2021, then plummeted by 30.08% to $8.4 million in 2022, then grew by 3.73% to $8.7 million in 2023, then decreased by 13.66% to $7.5 million in 2024, then fell by 24.81% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Finished Goods are $5.6 million (Q4 2025), $7.9 million (Q3 2025), and $8.9 million (Q2 2025).